IDEAS home Printed from https://ideas.repec.org/p/ohe/respap/002208.html
   My bibliography  Save this paper

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Author

Listed:
  • Neri, M.
  • Hampson, G.
  • Henshall, C.
  • Towse, A.

Abstract

Antimicrobial resistance (AMR) is a growing public health threat, limiting the ability of health care systems to prevent and treat infections and save lives. In parallel, global antibiotic development pipelines are weak. Various R&D incentives have been proposed to address the challenges associated to low economic returns from investment in antibiotics. Value assessment methods recognising the value of new antibiotics to the whole health system are needed to help match the size of the required monetary incentives to the value that they offer. At present, HTA methods for new antibiotics include benefits and costs associated with treating the immediate patient, while 'public health effects', such as preventing infection transmission and slowing down AMR development, are not captured. Furthermore, traditional pricing arrangements where revenues depend on volumes sold are unlikely to be profitable, as AMR stewardship will limit the use of the new antibiotic. Use may increase in the long-term when the build-up of resistance means that the antibiotic is used as a first line treatment. However, at that point in time the product may be off-patent and priced as a generic. This paper provides an overview of the current state of HTA and contracting for antibiotics in five European countries, and of the recent proposals in the literature for revising them. It also includes the recommendations developed following a stakeholder Forum on 'Value Assessment and Contracting for Antibiotics' held in February 2019.

Suggested Citation

  • Neri, M. & Hampson, G. & Henshall, C. & Towse, A., 2019. "HTA and Payment Mechanisms for New Drugs to Tackle AMR," Research Papers 002208, Office of Health Economics.
  • Handle: RePEc:ohe:respap:002208
    as

    Download full text from publisher

    File URL: https://www.ohe.org/system/files/private/publications/HTA%20and%20contracting%20for%20antibiotics%20report.pdf
    Download Restriction: no

    More about this item

    Keywords

    Judging value for money and improving decision making;

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:respap:002208. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Publications Manager). General contact details of provider: http://edirc.repec.org/data/ohecouk.html .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.